BMO Capital Maintains Market Perform on Amneal Pharmaceuticals, Lowers Price Target to $4

BMO Capital maintains Amneal Pharmaceuticals (NYSE:AMRX) with a Market Perform and lowers the price target from $5 to $4.

Benzinga · 11/11/2019 13:44

BMO Capital maintains Amneal Pharmaceuticals (NYSE:AMRX) with a Market Perform and lowers the price target from $5 to $4.